FinTechFunding

PharmAust: Begins recruiting dogs for canine cancer trial

  • PharmAust (PAA) has officially started recruiting patients for a second-phase clinical trial testing one of its key drugs against cancer in dogs
  • The phase IIb trial will test PharmAust’s monepantel (MPL) treatment against naive B-cell lymphoma in dogs
  • This is one of the most common types of cancer in dogs, accounting for around 20 per cent of all canine cancers
  • PharmAust has started treating eligible dogs with MPL under the trial and also started giving six dogs not eligible for the trial compassionate treatment
  • The company says the overall market for veterinary medicinal products is more than $22 billion
  • Shares in PharmAust closed grey this afternoon at 10 cents each
Previous article
BasisBank: Partners with Backbase to deliver hyper personalized experiences
Next article
SIA: Preliminary consolidated financial results at 31 December 2020 approved
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Former Royal Mint Executives Secure Backing for Precious Metals Trading Platform

New platform aims to modernize precious metals trading for investors.Highlights: Former Royal Mint executives launch a new trading...
FinTech

Coastal Bank Partners with Tempo to Strengthen Cross-Border Money Transfers

The partnership aims to enhance international money movement solutions.Highlights: Coastal Bank has partnered with Tempo for improved cross-border...
FinTech

Lloyds Accelerates Homebuying with Fully Digital Service

New platform aims to reduce waiting times for mortgage approvals.Highlights: Lloyds introduces a fully digital homebuying service.Service aims...
Blogs

AI in Fintech: Revolutionizing the Financial Industry

AI in fintech is changing how financial services operate. It's more than just a buzzword; it's a powerful...